Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘LLY-283’

An unexpected surprise!

Time for a fishing expedition or two

In our fifth preview from the AACR annual meeting being held in San Diego next month, we noticed some intriguing surprises emerging from one class of agents currently being studied both preclinically, as well as in the clinic.

What are they – and why do they matter?

Quite simply, once the implications are understood they may help us understand where the field is headed in the near to medium term – and why some particular combinations might yield some interesting findings…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

A new dawn for epigenetic therapy in oncology

A new dawn or a rapid sunset for epigenetics in oncology R&D?

Epigenetic therapies have had somewhat of a chequered history in oncology R&D, but new targets are always cropping up to tempt us to look further.

One emerging target we’ve come across – this is only the fourth mention here since January 2019 – is starting to gather steam with new players entering the landscape, as well as emerging preclinical and clinical evidence suggesting it might be well worth a serious look.

Here we look at the potential role this epigenetic target may have to play in a variety of difficult to treat cancers, as well as how it could enhance existing therapies in new combination approaches.

Could we combine these inhibitors with chemotherapy, with immunotherapy or DNA repair approaches?  How does the therapeutic window stack up?

We look at the latest evidence from several sources and discuss where the opportunities might lie…

To learn more from our oncology analysis and get a heads up on insights and commentary an emerging area of epigenetics, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!